Home Tags Solid Tumors

Tag: Solid Tumors

Initial Dose-Escalation of First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in...

An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

First Patient Dosed in Phase 1 Clinical Trial of ADC Therapeutics’...

A first patient has been dosed in a Phase 1 clinical trial evaluating ADCT-901, targeting kidney-associated antigen 1 (KAAG1), in patients with selected advanced...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

FDA Approves Sacituzumab Govitecan for Adult Patients with Unresectable Locally Advanced...

This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...

Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...

About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...

Tisotumab vedotin Demonstrates Encouraging Response Rate and a Manageable Safety Profile...

Preliminary clinical data for tisotumab vedotin, also known as HuMax®-TF-ADC from a Genmab-sponsored phase I/II clinical trial (GEN 701) were featured today in an...

Phase I Clinical Trial of Radioimmunotherapeutic FF-21101 Initiated in Patients with...

Earlier this week Strategia Therapeutics, an integrated pharmaceutical company, announced that it had initiated a Phase I clinical trial of Fujifilm's radioimmunotherapeutic agent FF-21101 (90Y) in...

Compugen’s Antibody Drug Conjugate Program Results Presented

This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...

Antigen Shedding and Targeted Delivery of Immunotoxins in Solid Tumors: A...

Cells modulate responses to signals in the extracellular environment by shedding cell surface antigens. Understanding this process is important because antibody-based anti-cancer therapies target...

X